

IDS 04/07/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10506748
	Filing Date	2004-09-03
	First Named Inventor	Alan Birch
	Art Unit	1625
	Examiner Name	SEAMAN, D MARGARET M
	Attorney Docket Number	100662-1P US

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
MS	1	01/32622	WO	A1	2001-05-10	AstraZeneca AB		<input type="checkbox"/>
MS	2	02/20530	WO	A1	2002-03-14	AstraZeneca AB		<input type="checkbox"/>
MS	3	03/074484	WO	A1	2003-09-12	AstraZeneca AB		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10506748	
		Filing Date		2004-09-03	
		First Named Inventor		Alan Birch	
		Art Unit		1625	
		Examiner Name		SEAMAN, D MARGARET M	
		Attorney Docket Number		100662-1P US	

MS	4	03/074485	WO	A2	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
MS	5	03/074517	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
MS	6	03/074531	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
MS	7	03/074532	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
MS	8	2004/031193	WO	A1	2004-04-15	AstraZeneca AB	<input type="checkbox"/>
MS	9	2004/031194	WO	A1	2004-04-15	AstraZeneca AB	<input type="checkbox"/>
MS	10	2001247565	JP	A	2001-09-11	Pfizer Prod Inc	<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
MS	1	Crochet, R.A., et al., J. Het. Chem., "Synthesis of Substituted Thieno[2,3-b] pyrroles," Vol. 11, 143-150 (April 1974).	<input type="checkbox"/>
MS	2	Teague, J., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," Diabetes, 52, Supp. 2, A365, 1521-P	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10506748
	Filing Date	2004-09-03
	First Named Inventor	Alan Birch
	Art Unit	1625
	Examiner Name	SEAMAN, D MARGARET M
	Attorney Docket Number	100662-1P US

MS	3	Vertigan, H., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," Diabetologia, 47, Supp.1, 589, A214. <input type="checkbox"/>
----	---	---

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/D Margaret Seaman/	Date Considered	05/16/2006
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

IDS - 04/05/2006

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

	Application Number	10506748
	Filing Date	2004-09-03
	First Named Inventor	Alan Martin Birch
	Art Unit	1625
	Examiner Name	Seaman, D Margaret M
	Attorney Docket Number	100662-1P US

U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
MS	1	4692522		1987-09-08	Parsons et al.			
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S.PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
MS	1	20040266768		2004-12-30	Schoenafinger et al.			
MS	2	20040142938		2004-07-22	Sher et al.			
MS	3	20040220229		2004-11-04	Bussolotti et al.			
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
MS	1	2004113345	WO	A1	2004-12-29	Japan Tobacco Inc.		<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10506748	
		Filing Date		2004-09-03	
		First Named Inventor			Alan Martin Birch
		Art Unit			1625
		Examiner Name		Seaman, D Margaret M	
		Attorney Docket Number		100662-1P US	

MS	2	03/045920	WO	A1	2003-06-05	Merck & Co., Inc.	<input type="checkbox"/>
MS	3	03/072570	WO	A1	2003-09-04	Pfizer Products Inc.	<input type="checkbox"/>
MS	4	1 340 500	EP	A1	2003-09-03	Pfizer Products Inc.	<input type="checkbox"/>
MS	5	2004/041780	WO	A2	2004-05-21	Pfizer Products Inc.	<input type="checkbox"/>
MS	6	2004/092158	WO	A1	2004-10-28	Pfizer Products Inc.	<input type="checkbox"/>
MS	7	1 338 594	EP	A1	2003-08-27	Shionogi & Co., Ltd.	<input type="checkbox"/>
MS	8	03/091213	WO	A1	2003-11-06	Yamanouchi Pharmaceutical Co., Ltd.	<input checked="" type="checkbox"/>
MS	9	2004196702	JP	A	2004-07-15	Yamanouchi Pharmaceutical Co., Ltd.	<input checked="" type="checkbox"/>
MS	10	2005/013981	WO	A1	2005-02-17	AstraZeneca AB	<input type="checkbox"/>
MS	11	2005/013975	WO	A1	2005-02-17	AstraZeneca AB	<input type="checkbox"/>
MS	12	2005/020986	WO	A1	2005-03-10	AstraZeneca AB	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10506748	
		Filing Date		2004-09-03	
		First Named Inventor		Alan Martin Birch	
		Art Unit		1625	
		Examiner Name		Seaman, D Margaret M	
		Attorney Docket Number		100662-1P US	

MS	13	2005/020985	WO	A1	2005-03-10	AstraZeneca AB	<input type="checkbox"/>
MS	14	2005/019172	WO	A1	2005-03-03	AstraZeneca AB	<input type="checkbox"/>
MS	15	2005/018637	WO	A1	2005-03-03	AstraZeneca AB	<input type="checkbox"/>
MS	16	2005/020987	WO	A1	2005-03-10	AstraZeneca AB	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
MS	1	Font, M. et al. "Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase", European Journal Med Chem (1995), 30(12), 963-71	<input type="checkbox"/>
MS	2	Lin, T. et al. "Effects of Protein Binding and Experimental Disease States on Brain Uptake of Benzodiazepines in Rats", J Pharmacology & Eptl Therapeutics (1990), 253(1), 45-50	<input type="checkbox"/>
MS	3	Varnavas, A. et al. "Quinolone Derivatives: Synthesis and Binding Evaluation on Cholecystokinin Receptors", Farmaco (1996), 51(5), 341-350	<input type="checkbox"/>
MS	4	Parsons, W H. et al. "Cholecystokinin Antagonists. Synthesis and Biological Evaluation of 3-Substituted Benzolactams", J Med Chem (1989), 32(8), 1681-5	<input type="checkbox"/>
MS	5	Vertigan, H. et al. "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents", EASD Munich 2004	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10506748
	Filing Date	2004-09-03
	First Named Inventor	Alan Martin Birch
	Art Unit	1625
	Examiner Name	Seaman, D Margaret M
	Attorney Docket Number	100662-1P US

MS	6	Bartlett, J. et al. "In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase", ADA San Diego 2005	<input type="checkbox"/>
MS	7	Green, A R. et al. "The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation", J Biol Chem, 279(45), 46474-46482, 2004	<input type="checkbox"/>
MS	8	Roberts, P A. et al. " The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle", J Physiology-London 545(1), 297-304, 2002	<input type="checkbox"/>
MS	9	Simpson, I. et al. "Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase", Cambridge Med Chem Conference, Sept 2005. Poster EOM	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button


EXAMINER SIGNATURE

Examiner Signature	/D Margaret Seaman/	Date Considered	05/16/2006/16/2006
--------------------	---------------------	-----------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.




Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete If Known	
				Application Number	10/506748
				Filing Date	September 3, 2004
				First Named Inventor	Alan Martin Birch
				Art Unit	1615
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	ASZD-P01-662

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AM	AA	US-2004/0002495-A1	01-01-2004	Philip Sher	
	AB	US-3,706,810	12-19-1972	AMERICAN CYANAMID	
	AC	US-4,599,198	07-08-1986	DENNIS J. HOOVER	
	AD	US-4,668,769	05-26-1987	DENNIS J. HOOVER	
	AE	US-4,720,503	01-19-1988	BRUCE E. WITZEL	
	AF	US-4,751,231	06-14-1988	WASYL HALCZENKO	
	AG	US-4,786,641	11-22-1988	SIEGFRIED GOLDMANN	
	AH	US-4,794,120	12-27-1988	PHILIPPE MANOURY	
	AI	US-5,863,903	01-26-1999	KARSTEN LUNDGREN	
	AJ	US-5,998,463	12-07-1999	BERNARD HULIN	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
AM	BA	WO-00/42213	07-20-2000	The Research Foundation of State University of New York	
	BB	WO-00/47206	08-17-2000	Novo Nordisk	
	BC	WO-01/05954	01-25-2001	Isis Pharmaceuticals, Inc.	
	BD	WO-01/23347	04-05-2001	Novo Nordisk	
	BE	WO-01/32654	05-10-2001	Societe de Conseils de Recherches et D'Applications Scientifiques	
	BF	WO-01/52825	07-26-2001	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	
	BG	WO-01/68055	09-20-2001	Pfizer Products Inc.	
	BH	WO-01/68092	09-20-2001	Pfizer Products Inc.	
	BI	WO-01/68603	09-20-2001	Bristol-Myers Squibb Co.	
	BJ	WO-01/94300	12-13-2001	Aventis Pharma Deutschland	
	BK	WO-01/96311	12-20-2001	Bristol-Myers Squibb Company	
	BL	WO-01/96347	12-20-2001	Bristol-Myers Squibb Company	
	BM	WO-02/080844	10-17-2002	Genzyme Corporation	
	BN	WO-02/096864	12-05-2002	Aventis Pharma Deutschland GmbH	
	BO	WO-02/098348	12-12-2002	Eli Lilly and Company	
	BP	WO-02/26714	04-04-2002	Takeda Chemical Industries, Ltd.	
	BQ	WO-02/34718	05-02-2002	Richter Gedeon Vegyeszeti Gyar Rt.	
	BR	WO-03/037864	05-08-2003	Japan Tobacco Inc.	
	BS	EP-0846464	08-10-1998	Pfizer Inc.	
	BT	EP-0884050	12-16-1998	Novo Nordisk	
	BU	EP-0978279	02-09-2000	Pfizer Products Inc.	
	BV	EP-1088824	01-07-2004	Pfizer Products Inc.	
	BW	EP-1125580	08-22-2001	Pfizer Products Inc.	
	BX	EP-1134213	09-19-2001	Pfizer Inc.	
	BY	EP-1136071	09-26-2001	Pfizer Products Inc.	

Examiner Signature	<i>AM</i>	Date Considered	5/10/2006
--------------------	-----------	-----------------	-----------



Approved for use through 07/31/2008. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/506748
				Filing Date	September 3, 2004
				First Named Inventor	Alan Martin Birch
				Art Unit	1615
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	ASZD-P01-662

AM	BZ	EP-1145717	05-12-2004	Pfizer Products Inc.		
	BA1	EP-1149580	02-21-2001	Pfizer Products Inc.		
	BB1	EP-1177791	07-27-2001	Pfizer Products Inc.		
	BC1	ES-2081747	03-01-1996	Esteve Labor DR		
	BD1	DE-4445968	06-27-1996	Bayer AG		
	BE1	WO-93/25574	12-23-1993	Pfizer Inc.		
	BF1	WO-95/24391	09-14-1995	Novo Nordisk		
	BG1	WO-96/39384	12-12-1996	Pfizer, Inc.		
	BH1	WO-96/39385	12-12-1996	Pfizer Inc.		
	BI1	WO-97/09040	03-13-1997	Novo Nordisk		
	BJ1	WO-97/31901	09-04-1997	Mikael Bots		
	BK1	WO-97/45425	12-04-1997	Fujisawa Pharmaceutical Co., Ltd.		
	BL1	WO-98/27108	06-25-1998	Fuji-Sawa Pharmaceutical Co., Ltd.		
	BM1	WO-98/40353	09-17-1998	Novo Nordisk		
	BN1	WO-98/50359	11-12-1998	Novo Nordisk		
	BO1	WO-99/26659	06-03-1999	Pfizer Products Inc.		
	BP1	WO-99/36393	07-22-1999	Tanabe Seiyaku Co., Ltd.		
	BQ1	JP 2001 089368				
	BR1	DD 200740	06-08-1983	Gewald		
	BS1	EP 697403	02-21-1996	Sanofi		
	BT1	JP 2001 206856	07-31-2001	Pfizer Prod. Inc.		
	BU1	JP 021247565	05-14-1990	Hanawa Netsuden Kinzoku KK Toray Ind. Inc.		
	BV1	JP 04179949	06-26-1992			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²	
AM	CA	Birch, A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, AstraZeneca UK, CVGI Research, Mereside, Alderley Park, Macclesfield, Cheshire.				
	CB	Crochet, R.A., et al., "Synthesis of Substituted Thieno[2,3-b] pyrroles," Vol. 11, 143-150 (April 1974).				
	CC	Freeman, S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 1470-P, A340.				
	CD	Hartman, G.D., et al., "The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides," Heterocycles, 29(10):1943-1949 (1989).				
	CE	Hoover, D.J., et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase," J. Med. Chem., 41:2934-2938 (1998).				
	CF	Hudson, S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 539:52-53 (2002).				
	CG	Jakobsen, P., et al., "Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase,"				
AM	Signature: <i>Amber</i>			Date Considered	5/16/2006	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



<p>Substitute for form 1449A/B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete If Known	
				Application Number	10/506748
				Filing Date	September 3, 2004
				First Named Inventor	Alan Martin Birch
				Art Unit	1615
Examiner Name	Not Yet Assigned				
Sheet	3	of	3	Attorney Docket Number	ASZD-P01-662

		Bioorganic Med. Chem., 9:733-744 (2001).
<i>M</i>	CH	Martin, W.H., et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo," PNAS, 95:1776-1781 (Feb. 1998).
<i>M</i>	CI	McCormack, J.G., et al., "Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy," Curr. Pharmaceutical Design, 7:1451-1474 (2001).
	CJ	Oikonomakos, N.G., et al., "Allosteric inhibition of glycogen phosphorylase alpha by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate," Protein Sci., 8:1930-1945 (1999).
	CK	Rath, V.L. et al., "Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core," Mol. Cell, 6:139-148 (July 2000).
	CL	Rosauer, K.G., et al., "Novel, 3,4-Dihydroquinolin-2(1H)-one Inhibitors of Human Glycogen Phosphorylase a," Bioorganic & Medicinal Chemistry Letters, 13:4385-4388 (2003).
	CM	Soman, G., et al. "Aromatic Compounds as Allosteric Inhibitors of Glycogen Phosphorylase beta," Biochimica et Biophysica Acta, 358:359-362 (1974).
	CN	Soman, G., et al., "The Nature of the Binding Site for Aromatic Compounds in Glycogen Phosphorylase beta," Biochem. J., 147:369-371 (1975).
	CO	Teague, J., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," Diabetes, 53, Supp. 1, A365, 1521-P
	CP	Treadway, J.L., et al., "Glycogen phosphorlase inhibitors for treatment of type 2 diabetes mellitus," Exp. Opin. Invest. Drugs, 10(3):439-454 (2001).
	CQ	Turnbull, A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 1485-P, A343.
<i>M</i>	CR	Venkatarangan, P., et al., "Prediction of Ligand-REceptor Binding Thermodynamics by Free Energy Force Field Three-Dimensional Quantitative Structure-Activity Relationship Analysis: Applications to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase," J. Med. Chem., 42:2169-2179 (1999).
<i>M</i>	CS	Vertigan, H., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," Diabetes, 47, Supp., 589, A214.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>(M)</i>	Date Considered	5/16/2005
--------------------	------------	-----------------	-----------